Existing medicines for antibody-related kidney transplant rejection
Official title: Computational Drug Repositioning for Antibody Mediated Renal Allograft Rejection
Funded at University of California, San Francisco · NIH-11321234 · Data updated 2026-11-12
This project looks for already-approved drugs or drug combinations that could calm harmful antibodies that attack kidney transplants.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | June 28, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $797,862 |
| NIH project number | 5R01AI180118-03 |
| Project ID | NIH-11321234 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with biopsy-confirmed antibody-mediated rejection after a kidney transplant would be the most relevant candidates for potential future testing or to provide samples.
✕Less likely to help
People without antibody-mediated rejection (for example, those with other causes of transplant dysfunction) or those unable to undergo biopsy-based sampling are unlikely to benefit directly from this project.
What this research studies
Researchers will analyze gene activity patterns from kidney transplant biopsies that show antibody-mediated rejection and from stable transplants. They will use computer tools and public drug-gene databases to find approved drugs that reverse the harmful molecular patterns. Promising single drugs and drug combinations will be tested in human cells and in biopsy tissue outside the body to study how they work. Successful leads would be advanced toward further testing in transplant patients.
Why it matters
Potential benefit: If successful, this work could identify existing drugs that slow or stop antibody-mediated rejection, offering quicker treatment options for transplant patients.
How similar studies have gone: Drug-repurposing methods have produced candidate treatments in other conditions and the investigators' preliminary analyses already point to leads for antibody-mediated rejection, but clinical benefit remains unproven.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Sarwal, Minnie M — University of California, San Francisco
- Study coordinator: Sarwal, Minnie M
Related research
Other NIH-funded projects on the same topics.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
Immunological mechanisms behind treatment-resistant kidney transplant rejection
This grant explores why certain kidney transplant rejections don’t respond to standard treatments and what immune cells in the graft are driving that resistance.
-
Targeting graft T cells to reduce transplant rejection
A patient-facing study exploring how immune cells within transplanted organs drive rejection and how we might reduce trouble for people who need organ transplants.
-
Engineered kidney 'chip' to study antibody-driven rejection and how the body adapts
A kidney-rejection research grant is developing a miniaturized, human cell–based chip to model how antibodies cause rejection and how kidneys may adapt.
-
Social media, mood, and teens: how the menstrual cycle affects rejection feelings and online experiences
Teenagers using social media may feel stronger negative reactions to online feedback, especially around certain times in their menstrual cycle, which could relate to mood and depression.
-
Understanding how BK virus links infection to kidney transplant rejection
This project looks at how BK polyomavirus reactivation affects kidney transplant patients and aims to use pre-transplant T cell information to tailor immunosuppression and monitoring.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.